All Updates

All Updates

icon
Filter
Funding
Opna Bio raises USD 38 million in Series A funding; launches from stealth
Precision Medicine
Nov 21, 2022
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Nov 21, 2022

Opna Bio raises USD 38 million in Series A funding; launches from stealth

Funding

  • Clinical-stage drug developer Opna Bio has launched from stealth and raised USD 38 million in a Series A funding round led by Longitude Capital and Northpond Ventures with participation from Menlo Ventures. 

  • The funds will be used to develop its new fragile-X mental retardation protein (FMRP) inhibitor for treating patients with solid tumors. Cancer cells use FRMP to hide from the immune system. Moreover, it plans to advance its portfolio of five preclinical and clinical small molecule drug candidates acquired from Plexxikon Inc. OPN-2853, the company's lead research program, is currently in Phase 1/2 clinical trials in combination with ruxolitinib to treat myelofibrosis, a chronic bone marrow cancer. Additionally, a Phase 2 study of OPN-7486 for treating solid tumors is planned for 2023. 

  • Opna Bio discovers and develops cancer treatments using a precision medicine approach. Former Plexxikon CEO Gideon Bollag co-founded the company after Plexxikon was shut down by its parent company and Japanese pharmaceutical giant Daiichi Sankyo in March 2022 . Opna Bio is now led by Gideon Bollag. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.